Last reviewed · How we verify

NCT04102839

PWS Outcomes Assessment Study

Completed Last updated 4 November 2024
What this trial tests

trial testing Interview in Prader-Willi Syndrome in 59 participants. Completed in 8 June 2021.

Timeline
15 July 2019
Primary endpoint
8 June 2021
8 June 2021

Quick facts

Lead sponsorSoleno Therapeutics, Inc.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment59
Start date15 July 2019
Primary completion8 June 2021
Estimated completion8 June 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Soleno Therapeutics, Inc. — full company profile →

Who can join

18 and older, any sex, with Prader-Willi Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a longitudinal study during which qualitative interviews will be conducted with caregivers of Soleno C601/C602 study subjects. There is an additional option for caregivers to collect video data of PWS patients doing specific activities of daily life. The purpose of this study is to understand the real-world and nuanced impact of a potential therapeutic on individual PWS patients. The results of this study will complement the outcomes being captured during the Soleno C601/C602 clinical studies. There is no treatment or intervention associated with this study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Interview

Trials testing the same drug.

Other recruiting trials for Prader-Willi Syndrome

Currently open trials in the same condition.

Other Soleno Therapeutics, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04102839.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing